AR075798A1 - Proteinas de union a il-17 (interleuquina 17) - Google Patents
Proteinas de union a il-17 (interleuquina 17)Info
- Publication number
- AR075798A1 AR075798A1 ARP100100680A ARP100100680A AR075798A1 AR 075798 A1 AR075798 A1 AR 075798A1 AR P100100680 A ARP100100680 A AR P100100680A AR P100100680 A ARP100100680 A AR P100100680A AR 075798 A1 AR075798 A1 AR 075798A1
- Authority
- AR
- Argentina
- Prior art keywords
- present
- cdr
- seq
- proteins
- interleuquina
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Proteínas de union a IL-17 y/o IL-17F, su uso en composiciones y métodos para el tratamiento, prevencion, y diagnostico de enfermedades relacionadas con IL-17 y para detectar IL-17 en células, tejidos, muestras y composiciones. Reivindicacion 1: Una proteína de union que comprende un dominio de union al antígeno capaz de unir IL-17 humana, caracterizada porque dicho dominio de union al antígeno comprende al menos una CDR que comprende una secuencia de aminoácidos seleccionada del grupo formado por: CDR-H 1. X1-X2-X3-X4-X5 (SEQ ID Ns:919), en donde; X1 es D o S; X2 es Y; X3 es E o G; X4.es l, M, V, o F; X5 es H; CDR-H2. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID Ns:920), en donde; X1 es V; X2 es T, 1, o N; X3 es D, H, o W; X4 es P o no está presente; X5 es E, G, o S; X6 es S, N, o D; X7 es G; X8 es G o T, X9 es T; X10 es L, A, T, o F; X11 es H o Y; X12 es N; X13 es P, Q, o S; X14 es K, A, o N; X15 es F o L; X16 es D, K, o R; y X17 es G, D, o S; CDR-H3. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID Ns:921), en donde; X1 es Y, F, o D; X2 es Y, L, S, o G; X3 es K, T, R, o Y; X4 es Y o W; X5 es E, D, o I; X6 es S, G, o Y; X7 es F, Y, o T; X8 es Y, F, o M; X9 es G, T, o no está presente; X10 es M o no está presente; X11 es D; y X12 es Y; CDR-L1. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16 (SEQ ID Ns:922), en donde; X1 es S, K, o R; X2 es A o S; X3 es S; X4 es S o Q; X5 es S o no está presente; X6 es L o no está presente; X7 es V o no está presente; X8 es H o no está presente; X9 es S o no está presente; X10 es S, N, o no está presente; X11 es S, V, o G; X12 es I, N, o S; X13 es S, N, T, o I; X14 es Y o D; X15 es M, V, L, o I; y X16 es C, A, H, Y, o G; CDR-L2. X1-X2-X3-X4-X5-X6-X7 (SEQ ID Ns:923), en donde; X1 es D, Y, K, A, o H; X2 es T, A, o V; X3 es S o F; X4 es K, N, o E; X5 es L o R; X6 es A, Y, o F; y X7 es S o T; y CDR-L3. X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID Ns:924), en donde; X1 es Q, S, o H; X2 es Q; X3 es R, D, S, o G; X4 es S, Y, o T; X5 es S, G, o H; X6 es Y, S, V, o A; X7 es P o no está presente; X8 es W, Y, o L; y X9 es T.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20927209P | 2009-03-05 | 2009-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075798A1 true AR075798A1 (es) | 2011-04-27 |
Family
ID=42710240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100680A AR075798A1 (es) | 2009-03-05 | 2010-03-05 | Proteinas de union a il-17 (interleuquina 17) |
Country Status (24)
Country | Link |
---|---|
US (7) | US8835610B2 (es) |
EP (4) | EP3235509A1 (es) |
JP (3) | JP5836807B2 (es) |
KR (2) | KR101579771B1 (es) |
CN (2) | CN105254758A (es) |
AR (1) | AR075798A1 (es) |
BR (1) | BRPI1013688A8 (es) |
CA (1) | CA2752648A1 (es) |
CL (2) | CL2011002129A1 (es) |
CO (1) | CO6410314A2 (es) |
CR (1) | CR20110470A (es) |
DO (1) | DOP2011000274A (es) |
EC (1) | ECSP11011297A (es) |
HK (2) | HK1202806A1 (es) |
IL (1) | IL214851A0 (es) |
MX (1) | MX2011009362A (es) |
NZ (2) | NZ611324A (es) |
PE (3) | PE20121094A1 (es) |
PH (1) | PH12015500093A1 (es) |
RU (2) | RU2011140335A (es) |
SG (2) | SG173705A1 (es) |
TW (2) | TW201613969A (es) |
UY (1) | UY32477A (es) |
WO (1) | WO2010102251A2 (es) |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
MX2010011955A (es) | 2008-04-29 | 2011-01-21 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US9035027B2 (en) * | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
SG173705A1 (en) | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
WO2010128407A2 (en) | 2009-05-05 | 2010-11-11 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
CA2771575A1 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
CA2772628A1 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
PE20130580A1 (es) | 2010-03-02 | 2013-06-02 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
WO2011144749A1 (en) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Biological materials related to her3 |
AU2011285852B2 (en) * | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
EP3111954B1 (en) | 2010-11-05 | 2019-04-03 | Novartis Ag | Methods of treating ankylosing spondylitis using anti-il-17 antibodies |
BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
UY33827A (es) * | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
EP2655415A4 (en) * | 2010-12-22 | 2016-03-09 | Abbvie Inc | THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF |
WO2012094300A2 (en) * | 2011-01-04 | 2012-07-12 | The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health | Methods of treating age-related macular degeneration |
EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
CN109021069A (zh) | 2011-01-18 | 2018-12-18 | 比奥尼斯有限责任公司 | 调节γ-C-细胞因子活性的组合物及方法 |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
US8999331B2 (en) | 2011-10-24 | 2015-04-07 | Abbvie Inc. | Immunobinders directed against sclerostin |
CN104093739A (zh) | 2011-10-24 | 2014-10-08 | 艾伯维公司 | 针对tnf的免疫结合剂 |
RS20140202A1 (en) * | 2011-10-24 | 2014-10-31 | Abbvie Inc. | BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17 |
CN104011207B (zh) | 2011-10-31 | 2018-09-18 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
US9198900B2 (en) | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
EP2597102A1 (en) | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
TW201333035A (zh) * | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
EP2812445A2 (en) | 2012-02-10 | 2014-12-17 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
KR101674784B1 (ko) * | 2012-04-05 | 2016-11-09 | 에프. 호프만-라 로슈 아게 | 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도 |
WO2013164440A1 (en) | 2012-05-03 | 2013-11-07 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
CN104884473B (zh) | 2012-05-22 | 2019-12-03 | 百时美施贵宝公司 | Il-17a/f il-23双特异性抗体及其应用 |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
JP2016506720A (ja) | 2013-01-21 | 2016-03-07 | アッヴィ・インコーポレイテッド | 炎症性疾患のための抗tnf及び抗il17併用治療薬バイオマーカー |
UY35315A (es) * | 2013-02-08 | 2014-09-30 | Novartis Ag | Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios |
TW201444867A (zh) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗tnf-抗il-17雙特異性抗體 |
CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CA3182572A1 (en) * | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
DK2992104T3 (da) | 2013-05-03 | 2019-07-15 | Fujifilm Diosynth Biotechnologies Uk Ltd | Fremgangsmåde til ekspression |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
WO2015014979A1 (en) * | 2013-08-01 | 2015-02-05 | F. Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
JP6560673B2 (ja) * | 2013-08-19 | 2019-08-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ハイドロキシアパタイトクロマトグラフィーを用いた二重特異性抗体および二重特異性抗体生産副産物の分離法 |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CN110305095A (zh) | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
CA2929662C (en) * | 2013-11-18 | 2023-05-02 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-17a binding agent and uses thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US20150224078A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers |
PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
US20150291689A1 (en) * | 2014-03-09 | 2015-10-15 | Abbvie, Inc. | Compositions and Methods for Treating Rheumatoid Arthritis |
AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
CN104311670B (zh) * | 2014-04-23 | 2017-05-17 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL‑17和TNFα的融合多肽及其应用 |
WO2015174439A1 (ja) | 2014-05-13 | 2015-11-19 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子 |
WO2015191760A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
US10561805B2 (en) * | 2014-10-10 | 2020-02-18 | Ablynx N.V. | Methods of treating RSV infections |
WO2016070062A2 (en) * | 2014-10-31 | 2016-05-06 | Genentech, Inc. | Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same |
US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
PT3065748T (pt) | 2014-12-23 | 2018-02-28 | 4D Pharma Res Ltd | Uma estirpe de bacteroides thetaiotaomicron e o seu uso na redução da inflamação |
CA2970234A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
AU2016208161B2 (en) * | 2015-01-12 | 2020-01-16 | Affibody Ab | IL-17A-binding polypeptides |
GB201500463D0 (en) * | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
US20160244520A1 (en) | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
JP6507267B2 (ja) | 2015-05-22 | 2019-04-24 | チョン クン ダン ファーマシューティカル コーポレーション | 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物 |
TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
CA2988693A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
RS63089B1 (sr) | 2015-06-15 | 2022-04-29 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
KR20180020169A (ko) | 2015-06-24 | 2018-02-27 | 에프. 호프만-라 로슈 아게 | 조정된 친화도를 갖는 항-트랜스페린 수용체 항체 |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
CN114057885A (zh) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CA3000207A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
LT3370770T (lt) | 2015-11-03 | 2021-04-12 | Janssen Biotech, Inc. | Anti-cd38 antikūnų poodinės kompozicijos ir jų panaudojimas |
US10988543B2 (en) | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
US9839655B2 (en) | 2015-11-20 | 2017-12-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
WO2017091644A1 (en) * | 2015-11-23 | 2017-06-01 | Aztherapies, Inc. | Compositions and methods for treating ischemic stroke |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
MY189113A (en) | 2016-03-02 | 2022-01-26 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
MX2018010680A (es) | 2016-03-04 | 2019-06-13 | 4D Pharma Plc | Composiciones que comprenden cepas bacterianas. |
SG11201807936VA (en) | 2016-03-14 | 2018-10-30 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
WO2018045217A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
CA3036913C (en) | 2016-09-14 | 2023-05-16 | Beijing Hanmi Pharm. Co., Ltd. | Antibody specifically binding to il-17a and functional fragment thereof |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
WO2018085407A1 (en) | 2016-11-02 | 2018-05-11 | Nanoproteagen | Polymeric nanoparticles |
JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
AU2017363300A1 (en) | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2018105708A1 (ja) | 2016-12-07 | 2018-06-14 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
MA48941A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
ES2917415T3 (es) | 2017-06-14 | 2022-07-08 | 4D Pharma Res Ltd | Composiciones que comprenden una cepa bacteriana |
CA3070386A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
CN108359011B (zh) * | 2017-07-21 | 2019-06-25 | 华博生物医药技术(上海)有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
CN111465612A (zh) | 2017-10-13 | 2020-07-28 | 哈普恩治疗公司 | B细胞成熟抗原结合蛋白 |
AU2018347582A1 (en) | 2017-10-13 | 2020-05-07 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
WO2020010049A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE |
US20220017626A1 (en) * | 2018-09-21 | 2022-01-20 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
US11352421B2 (en) * | 2018-12-11 | 2022-06-07 | Rush University Medical Center | Treatment for adverse immune reaction to metal implant debris |
EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
KR20210122243A (ko) * | 2019-01-31 | 2021-10-08 | 누맙 세러퓨틱스 아게 | TNFα 및 IL-17A에 대한 특이성을 가지는 다중 특이적 항체, IL-17A를 표적화하는 항체, 그리고 이의 사용 방법 |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
KR20220012256A (ko) * | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
WO2021011353A1 (en) * | 2019-07-12 | 2021-01-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
US11807687B2 (en) | 2019-10-03 | 2023-11-07 | Atyr Pharma, Inc. | Therapeutic compositions comprising anti-NRP2 antibodies |
AU2021208482A1 (en) | 2020-01-13 | 2022-07-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
EP4106806A1 (en) | 2020-02-21 | 2022-12-28 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
CA3174680A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
US11197910B1 (en) | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
CN112538526B (zh) * | 2020-12-10 | 2023-03-17 | 中山大学附属第五医院 | Slamf7重组蛋白在制备治疗脓毒症药物中的应用 |
WO2023076998A1 (en) * | 2021-10-27 | 2023-05-04 | Atyr Pharma, Inc. | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES |
CN114283896B (zh) * | 2021-12-23 | 2022-11-18 | 江南大学 | 一种监测酶促反应过程中组分变化模型的建模方法 |
CN114920838B (zh) * | 2022-03-25 | 2023-11-24 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
Family Cites Families (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
DE3588239T3 (de) | 1985-03-30 | 2007-03-08 | Kauffman, Stuart A., Santa Fe | Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3750503T2 (de) | 1986-10-22 | 1995-02-09 | Abbott Lab | Chemilumineszierende Acridinium- und Phenantridiniumsalze. |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) * | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
SE462454B (sv) * | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
EP0550436A1 (en) * | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) * | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス, インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ATE177782T1 (de) | 1990-12-20 | 1999-04-15 | Ixsys Inc | Optimierung von bindenden proteinen |
ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
SK281142B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
WO1993020442A1 (en) | 1992-03-30 | 1993-10-14 | Abbott Laboratories | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5565352A (en) * | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
EP0771208B1 (en) | 1994-08-12 | 2005-10-19 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
JPH10511957A (ja) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | 表面改質ナノ微粒子並びにその製造及び使用方法 |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | PRODUCTION OF LARGE GENOMIC DNA DELETIONS |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
SK284040B6 (sk) * | 1996-02-09 | 2004-08-03 | Abbott Laboratories (Bermuda) Ltd. | Ľudské protilátky k ľudskému TNFalfa, ich použitie, spôsob ich syntézy a farmaceutické prípravky s ich obsahom |
US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
JP3692542B2 (ja) | 1997-01-21 | 2005-09-07 | ザ ジェネラル ホスピタル コーポレーション | Rna−蛋白質の融合体を用いた蛋白質の選抜 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
EP1007967A2 (en) | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 cd147 결합 분자 |
EP1068356B8 (en) | 1998-04-03 | 2007-01-03 | Adnexus Therapeutics, Inc. | Addressable protein arrays |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
DK2112166T3 (en) | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
HUP0301208A2 (hu) * | 1999-02-12 | 2003-08-28 | Genetics Institute, Llc | B7-molekulákkal reagáló humanizált immunglobulin és az ezekkel végzett kezelési eljárások |
WO2000056934A1 (en) | 1999-03-24 | 2000-09-28 | Packard Bioscience Company | Continuous porous matrix arrays |
PL218748B1 (pl) | 1999-03-25 | 2015-01-30 | Abbott Gmbh & Co Kg | Wyizolowane przeciwciało ludzkie lub jego część wiążąca antygen, zawierająca je kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiej IL-12 in vitro, zastosowanie przeciwciała lub jego części wiążącej antygen, sposób wykrywania ludzkiej IL-12, wyizolowana cząsteczka kwasu nukleinowego, zrekombinowany wektor ekspresyjny, komórka gospodarz oraz sposób syntetyzowania ludzkiego przeciwciała lub jego części wiążącej antygen |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
SK12232002A3 (sk) | 2000-02-25 | 2003-03-04 | The Government Of The United States, As Represented By The | Anti-ERGFRvIII scFv so zlepšenou cytotoxicitou a výťažkom, imunotoxíny a spôsoby ich použitia |
AU2001262116A1 (en) | 2000-03-20 | 2001-10-03 | Dsm N.V. | Talaromyces emersonii beta-glucanases |
AU2001255196A1 (en) * | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
WO2001077342A1 (en) | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
DE60116753T2 (de) | 2000-05-19 | 2006-09-14 | Scancell Ltd. | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor |
EP1522590B1 (en) | 2000-06-28 | 2009-08-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
US7449308B2 (en) * | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
ATE420958T1 (de) | 2000-06-29 | 2009-01-15 | Abbott Lab | Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung |
EP2325205A3 (en) * | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
CA2450285C (en) * | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
ES2327905T3 (es) * | 2001-10-01 | 2009-11-05 | Dyax Corp. | Vectores de presentacion eucariotas multi-cadena y usos de los mismos. |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
AU2002346373A1 (en) | 2001-11-09 | 2003-05-19 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20040244030A1 (en) | 2001-11-10 | 2004-12-02 | Boyce Jill Mac Donald | Video recording system and method for a plurality of individual users and catergories of users |
DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
KR20130135986A (ko) | 2003-03-05 | 2013-12-11 | 할로자임, 아이엔씨 | 가용성 하이알우로니다제 당단백질 (sHASEGP), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물 |
JP2007525195A (ja) * | 2003-06-02 | 2007-09-06 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒト慢性リンパ球性白血病に関連する細胞表面タンパク質 |
CA2537055A1 (en) * | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
US7723099B2 (en) * | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
ATE537189T1 (de) | 2004-04-30 | 2011-12-15 | Inst Nat Sante Rech Med | Anti-tfr-antikörper |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
TW200635608A (en) | 2004-12-15 | 2006-10-16 | Neuralab Ltd | Aβ antibodies for use in improving cognition |
AR052289A1 (es) | 2005-02-14 | 2007-03-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos |
US7807159B2 (en) | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
KR20130080058A (ko) * | 2005-06-30 | 2013-07-11 | 아보트 러보러터리즈 | Il-12/p40 결합 단백질 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500352A1 (en) * | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP5063612B2 (ja) * | 2005-12-13 | 2012-10-31 | イーライ リリー アンド カンパニー | 抗il−17抗体 |
GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
ATE467640T1 (de) * | 2006-02-10 | 2010-05-15 | Zymogenetics Inc | Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
US7883855B2 (en) * | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
KR101218484B1 (ko) | 2006-08-11 | 2013-01-04 | 머크 샤프 앤드 돔 코포레이션 | Il-17a에 대한 항체 |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
CA2672229A1 (en) | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
CA2673314C (en) | 2006-12-29 | 2014-03-11 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
DE602008004296D1 (de) * | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
CN101951953A (zh) | 2007-02-27 | 2011-01-19 | 株式会社未来创药研究所 | 含抗grp78抗体作为有效成分的药物组合物 |
US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
MX2010011955A (es) | 2008-04-29 | 2011-01-21 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
US9035027B2 (en) | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AU2009298501A1 (en) | 2008-09-30 | 2010-04-08 | Abbvie Inc. | Improved antibody libraries |
EP2370820B1 (en) | 2008-12-31 | 2016-02-24 | Abbott Point Of Care, Inc. | Method and device for immunoassay using nucleotide conjugates |
SG173705A1 (en) | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
-
2010
- 2010-03-05 SG SG2011058773A patent/SG173705A1/en unknown
- 2010-03-05 JP JP2011553150A patent/JP5836807B2/ja not_active Expired - Fee Related
- 2010-03-05 PE PE2011001585A patent/PE20121094A1/es not_active Application Discontinuation
- 2010-03-05 AR ARP100100680A patent/AR075798A1/es unknown
- 2010-03-05 RU RU2011140335/10A patent/RU2011140335A/ru not_active Application Discontinuation
- 2010-03-05 PE PE2016000576A patent/PE20160651A1/es not_active Application Discontinuation
- 2010-03-05 MX MX2011009362A patent/MX2011009362A/es active IP Right Grant
- 2010-03-05 EP EP17168290.9A patent/EP3235509A1/en not_active Withdrawn
- 2010-03-05 RU RU2015132478/10A patent/RU2015132478A/ru not_active Application Discontinuation
- 2010-03-05 SG SG10201402960SA patent/SG10201402960SA/en unknown
- 2010-03-05 TW TW105100969A patent/TW201613969A/zh unknown
- 2010-03-05 CN CN201510741911.4A patent/CN105254758A/zh active Pending
- 2010-03-05 US US12/718,841 patent/US8835610B2/en active Active
- 2010-03-05 KR KR1020117023029A patent/KR101579771B1/ko not_active IP Right Cessation
- 2010-03-05 TW TW099106520A patent/TWI541021B/zh not_active IP Right Cessation
- 2010-03-05 BR BRPI1013688A patent/BRPI1013688A8/pt not_active IP Right Cessation
- 2010-03-05 PE PE2016000719A patent/PE20160653A1/es not_active Application Discontinuation
- 2010-03-05 EP EP10749415A patent/EP2403531A4/en not_active Withdrawn
- 2010-03-05 EP EP14172004.5A patent/EP2810652A3/en not_active Withdrawn
- 2010-03-05 CA CA2752648A patent/CA2752648A1/en not_active Abandoned
- 2010-03-05 NZ NZ611324A patent/NZ611324A/en not_active IP Right Cessation
- 2010-03-05 UY UY0001032477A patent/UY32477A/es not_active Application Discontinuation
- 2010-03-05 EP EP14162807.3A patent/EP2772269A3/en not_active Withdrawn
- 2010-03-05 WO PCT/US2010/026424 patent/WO2010102251A2/en active Application Filing
- 2010-03-05 KR KR1020157001812A patent/KR20150018646A/ko not_active Application Discontinuation
- 2010-03-05 CN CN201080019710.9A patent/CN102781470B/zh not_active Expired - Fee Related
- 2010-03-05 NZ NZ594514A patent/NZ594514A/xx not_active IP Right Cessation
-
2011
- 2011-08-25 IL IL214851A patent/IL214851A0/en unknown
- 2011-08-25 CO CO11108934A patent/CO6410314A2/es unknown
- 2011-09-01 CL CL2011002129A patent/CL2011002129A1/es unknown
- 2011-09-01 CR CR20110470A patent/CR20110470A/es unknown
- 2011-09-01 EC EC2011011297A patent/ECSP11011297A/es unknown
- 2011-09-02 DO DO2011000274A patent/DOP2011000274A/es unknown
-
2012
- 2012-07-04 HK HK15103435.0A patent/HK1202806A1/xx unknown
- 2012-07-04 HK HK15100711.1A patent/HK1200320A1/xx unknown
-
2013
- 2013-08-05 US US13/959,648 patent/US8779101B2/en active Active
- 2013-12-18 CL CL2013003640A patent/CL2013003640A1/es unknown
-
2014
- 2014-04-22 US US14/258,994 patent/US20140335564A1/en not_active Abandoned
- 2014-04-23 US US14/260,197 patent/US20140348834A1/en not_active Abandoned
- 2014-04-24 US US14/261,257 patent/US9481735B2/en active Active
- 2014-04-25 US US14/262,653 patent/US9663587B2/en active Active
- 2014-04-28 US US14/263,724 patent/US9481736B2/en active Active
-
2015
- 2015-01-14 PH PH12015500093A patent/PH12015500093A1/en unknown
- 2015-01-27 JP JP2015013441A patent/JP5819013B2/ja not_active Expired - Fee Related
- 2015-09-25 JP JP2015187744A patent/JP2016047820A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR075798A1 (es) | Proteinas de union a il-17 (interleuquina 17) | |
AR078778A1 (es) | Proteinas de union a antigenos de il-23 | |
AR066794A1 (es) | Proteina de union que comprende un dominio de union a antigeno que se une al globulomero beta amiloide (20-42), anticuerpos, molecula de acido nucleico que la codifica vector, celula huesped, metodo para su produccion, usos, composicion farmaceutia y metodo de diagnostico | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
NZ603972A (en) | Anti-fgfr2 antibodies | |
AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
JP2020536109A5 (es) | ||
EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
JP2014512809A5 (es) | ||
NZ628792A (en) | Il-1 binding proteins | |
JP2016512214A5 (es) | ||
CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
AU2010217100A8 (en) | Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes | |
JP2017508475A5 (es) | ||
RS54302B1 (en) | EPITOPES OF IL-17A AND IL-17F AND THEIR SPECIFIC ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |